SÍNDROME DE STEVENS-JOHNSON CON COMPROMISO MUCOCUTÁNEO SEVERO ASOCIADO A MYCOPLASMA PNEUMONIAE EN UN ESCOLAR: REPORTE DE CASO
Authors/Creators
- 1. Hospital General del IESS – Ambato. Universidad Técnica de Ambato, Facultad de Ciencias de la Salud. Ambato, Ecuador
Description
Tipo de artículo: Caso clínico
Introducción. El síndrome de Stevens-Johnson es una reacción mucocutánea grave que provoca necrosis epidérmica, descamación de la piel y un compromiso severo de múltiples mucosas. Aunque su incidencia en la población pediátrica es baja, exige una intervención médica inmediata debido al alto riesgo de complicaciones sistémicas y secuelas a largo plazo.
Caso clínico: Escolar masculino de 7 años con antecedentes de infecciones respiratorias recurrentes, quien acudió por un cuadro de 15 días de evolución caracterizado por odinofagia, fiebre, tos productiva y lesiones mucocutáneas progresivas. A la exploración física se observaron lesiones ampollosas y necróticas en la mucosa oral, pápulas eritematosas cutáneas, edema facial e hiperemia conjuntival bilateral con secreción purulenta. Los estudios de laboratorio reportaron leucocitosis con neutrofilia, elevación de la proteína C reactiva y serología positiva para Mycoplasma pneumoniae. Se estableció el diagnóstico de síndrome de Stevens-Johnson secundario a infección por M. pneumoniae. Tras instaurar medidas de soporte y antibioticoterapia específica, el paciente evolucionó favorablemente.
Conclusión: El síndrome de Stevens-Johnson desencadenado por Mycoplasma pneumoniae requiere un alto índice de sospecha en pediatría. Reconocer esta condición rápidamente, la cual puede superponerse clínicamente a la erupción y mucositis inducidas por Mycoplasma, es clave para evitar retrasos diagnósticos, optimizar el tratamiento de soporte con antibióticos dirigidos y asistir en las decisiones clínicas en urgencias pediátricas.
Abstract (English)
Article type: Clinical case
Introduction. Stevens-Johnson syndrome is a severe mucocutaneous reaction characterised by epidermal necrosis, skin desquamation, and severe involvement of multiple mucous membranes. Although its incidence in the pediatric population is low, it requires immediate medical intervention due to the high risk of systemic complications and long-term sequelae.
Case report: A 7-year-old male schoolchild with a history of recurrent respiratory infections presented with a 15-day history of odynophagia, fever, productive cough, and progressive mucocutaneous lesions. Physical examination revealed bullous and necrotic lesions in the oral mucosa, erythematous cutaneous papules, facial edema, and bilateral conjunctival hyperemia with purulent discharge. Laboratory findings reported leukocytosis with neutrophilia, elevated C-reactive protein, and positive serology for Mycoplasma pneumoniae. A diagnosis of Stevens-Johnson syndrome secondary to M. pneumoniae infection was established. Following the initiation of supportive care and targeted antibiotic therapy, the patient showed a favourable clinical course.
Conclusion: Stevens-Johnson syndrome triggered by Mycoplasma pneumoniae requires a high index of suspicion in paediatrics. Prompt recognition of this condition, which can clinically overlap with Mycoplasma-induced rash and mucositis, is crucial to prevent diagnostic delays, optimise supportive care with targeted antibiotics, and guide clinical decision-making in pediatric emergency departments.
Files
sanum_v10_n4_a15.pdf
Additional details
Additional titles
- Translated title (English)
- STEVENS–JOHNSON SYNDROME WITH SEVERE MUCOCUTANEOUS INVOLVEMENT ASSOCIATED WITH MYCOPLASMA PNEUMONIAE IN A SCHOOL-AGED PATIENT: A CASE REPORT
Dates
- Collected
-
2026-07-01manuscrito recibido
- Accepted
-
2026-08-04evaluación doble ciego
- Available
-
2026-10-30publicación en numero de la revista
Software
- Repository URL
- https://revistacientificasanum.com/
- Development Status
- Active
References
- 1. Hama N, Aoki S, Chen CB, Hasegawa A, Ogawa Y, Vocanson M, et al. Recent progress in Stevens–Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. British Journal of Dermatology [Internet]. 2024 [consultado 2025 Nov 6];192(1):9–18. Disponible en: https://doi.org/10.1093/bjd/ljae321 2. Bataille P, Lebrun‐Vignes B, Bettuzzi T, Ingen‐Housz‐Oro S, Hadj‐Rabia S, Welfringer‐Morin A, et al. Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis. Journal of the European Academy of Dermatology and Venereology [Internet]. 2024 [consultado 2025 Nov 15];38(9):1791–8. Disponible en: https://doi.org/10.1111/jdv.20054 3. Chi M, Chung W, Hui RC, Chen C, Lu C, Chiu T, et al. Clinical features and outcomes in children with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Dermatol [Internet]. 2022 [consultado 2025 Nov 24];49(9):895–902. Disponible en: https://doi.org/10.1111/1346-8138.16476 4. Creighton R, Gupta S, Langille C, Sutherland A. Diagnosis and Management of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Patients: A Systematic Review of Clinical Guidelines and Consensus Statements. Pediatr Dermatol [Internet]. 2026 [consultado 2025 Dic 3];43(3):579–89. Disponible en: https://doi.org/10.1111/pde.70149 5. Chen YL, Tsai TY, Pan LY, Tsai YJ, Chen SY, Hsiao CH, et al. Ocular Manifestations and Outcomes in Children With Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Comparison With Adult Patients. Am J Ophthalmol [Internet]. 2023 [consultado 2025 Dic 12];256:108–17. Disponible en: https://doi.org/10.1016/j.ajo.2023.08.009 6. Abtahi-Naeini B, Dehghan M sadegh, Paknazar F, Shahmoradi Z, Faghihi G, Sabzghabaee AM, et al. Clinical and Epidemiological Features of Patients with Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iran: Different Points of Children from Adults. Int J Pediatr [Internet]. 2022 [consultado 2025 Dic 22];2022:1–10. Disponible en: https://doi.org/10.1155/2022/8163588 7. Cool D, Nguyen V, Zhang S, Seo S, Dai S. Mycoplasma‐Induced Rash and Mucositis: Ocular Manifestations, Treatment and Outcomes in a Paediatric Population. J Paediatr Child Health [Internet]. 2025 [consultado 2026 Ene 5];61(8):1263–9. Disponible en: https://doi.org/10.1111/jpc.70103 8. D'Agostino S, Granberg V, Valentini G, Corsalini M, Limongelli L. Mucositis Associated with Mycoplasma pneumoniae: Systematic Review and Case Series. Children [Internet]. 2026 [consultado 2026 Ene 17];13(5):638. Disponible en: https://doi.org/10.3390/children13050638 9. Shao Q hui, Yin X dong, Zeng N, Zhou Z xuan, Mao X yu, Zhu Y, et al. Stevens-Johnson Syndrome Following Non-steroidal Anti-inflammatory Drugs: A Real-World Analysis of Post-marketing Surveillance Data. Front Pediatr [Internet]. 2022 [consultado 2026 Ene 29];10. Disponible en: https://doi.org/10.3389/fped.2022.896867 10. Beheshti R, Cusack B. Atypical Stevens-Johnson Syndrome Associated With Mycoplasma Pneumoniae. Cureus [Internet]. 2022 [consultado 2026 Feb 7]; Disponible en: https://doi.org/10.7759/cureus.21825 11. Narang P, D'Souza S. Chronic Ocular Sequelae of Stevens-Johnson Syndrome: Recent Advances in Understanding of Patho-Physiology and Management. Semin Ophthalmol [Internet]. 2026 [consultado 2026 Feb 18];41(2):320–30. Disponible en: https://doi.org/10.1080/08820538.2025.2545264 12. Ramien ML, Mansour D, Shear NH. Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN. Paediatr Drugs [Internet]. 2022 [consultado 2026 Feb 26];24(4):307–19. Disponible en: https://doi.org/10.1007/s40272-022-00515-0 13. Shields BE, Wanat KA, Chiu YE. Undiagnosed and Rare Diseases in Critical Care: Severe Mucocutaneous Medication Reactions. Crit Care Clin [Internet]. 2022 [consultado 2026 Mar 5];38(2):243–69. Disponible en: https://doi.org/10.1016/j.ccc.2021.11.003 14. Tardeh S, Sarmad A, Otaghi M, Heydari F, Adibi A, Malekan Z, et al. The Prevalence of Stevens–Johnson Syndrome Complications due to Antiepileptic Drug Use: A Systematic Review and Meta-Analysis. Int J Prev Med [Internet]. 2025 [consultado 2026 Mar 12];16. Disponible en: https://doi.org/10.4103/ijpvm.ijpvm_132_24 15. Liew YCC, Choo KJL, Oh CC, Pang SM, Yeo YW, Lee HY. Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center. J Am Acad Dermatol [Internet]. 2022 [consultado 2026 Mar 19];86(4):811–7. Disponible en: https://doi.org/10.1016/j.jaad.2021.04.066 16. Howell JL, Cochran AL, Neaves BI, Coop CA. An Uncommon Reaction to a Common Medication: Stevens-Johnson Syndrome Associated With Azithromycin. Mil Med [Internet]. 2026 [consultado 2026 Mar 24];191(5–6):e1314–8. Disponible en: https://doi.org/10.1093/milmed/usaf352 17. Pejčić A V. Stevens‐Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. Int J Dermatol [Internet]. 2021 [consultado 2026 Mar 27];60(1):12–24. Disponible en: https://doi.org/10.1111/ijd.15144 18. Wang YS, Zhou YL, Bai GN, Li SX, Xu D, Chen LN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World Journal of Pediatrics [Internet]. 2024 [consultado 2026 Mar 29];20(9):901–14. Disponible en: https://doi.org/10.1007/s12519-024-00831-0 19. Akgun Z, Can GD, Selver OB. Ocular involvement in Stevens–Johnson syndrome and toxic epidermal necrolysis: A review of current management and changing trends. Indian J Ophthalmol [Internet]. 2025 [consultado 2026 Mar 31];73(12):1711–22. Disponible en: https://doi.org/10.4103/IJO.IJO_1119_25 20. Hassanpour K, Asadigandomani H, Soltani Shahgoli S, Amoozadehsamakoosh A, Soleimani M. Ocular Complications in stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Comprehensive Review. Semin Ophthalmol [Internet]. 2026 [consultado 2026 Abr 1];41(2):356–70. Disponible en: https://doi.org/10.1080/08820538.2025.2548869